Evonik Evonik

X
[{"orgOrder":0,"company":"Inventage Lab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inventage Lab Introduces \u2018One-Month Long-Acting\u2019 Drug Addiction Injection on the International Stage","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"Approved","date":"October 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I"}]

Find Clinical Drug Pipeline Developments & Deals by Inventage Lab

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            IVL3004 (naltrexone) is an opiod antagonist. It is a one-month long-acting injection based on company's IVL-DrugFluidic® technology. It is designed to treat opioid addiction.

            Lead Product(s): Naltrexone

            Therapeutic Area: Psychiatry/Psychology Product Name: IVL3004

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 06, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY